Merit Medical Systems (Nasdaq:MMSI) announced today that it received FDA clearance for its Scout Bx delivery system.
South Jordan, Utah-based Merit said in a news release that the technology represents the first wire-free breast localization solution that can be deployed at the time of stereotactic or MRI-guided biopsy.
The company designed Scout Bx to be compatible with the most commonly used stereotactic and MRI-guided breast biopsy devices on the market so patients can avoid an additional procedure.
Dr. Brett T. Parkinson, a diagnostic radiologist at Intermountain Healthcare in Salt Lake City and a consultant of Merit, said in the release that the system provides clinicians with a streamlined pathway to a broader group of patients without a requirement for the patient to undergo a second procedure.
“The Scout system is the market leader in wire-free breast surgical localization. Merit is committed to maintaining this leadership through continuous innovation to advance and streamline treatment for cancer patients,” Merit Medical Chairperson and CEO Fred P. Lampropoulos said in the release. “Placement at the time of biopsy lessens the burden on cancer patients and benefits healthcare providers. The Scout Bx system expands this important treatment option to more patients. Merit is proud to be the first to market with this solution.”